Skip to main content

Advertisement

Notice to Authors

Journal for ImmunoTherapy of Cancer will no longer be published by BMC as of 2020. The journal is continuing in cooperation with a new publisher, BMJ


Effective, as of October 10, 2019: to submit your manuscript to JITC, please visit the new submission system at https://mc.manuscriptcentral.com/jitc

If you have any questions regarding submission to the new peer review system, or require assistance submitting your manuscript, please contact the Editorial Assistant (info.jitc@bmj.com).

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. 

Read more, explore our article types and sections, and submit your manuscript.

Articles

SITC Member Discount

SITC will provide members with a 60 percent discount on article processing charges for all JITC articles submitted and accepted in 2019.

For any questions regarding the discount, please contact JITCEditor@sitcancer.org. 

Society affiliation

Learn more about the Society for Immunotherapy of Cancer’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy at SITC Cancer Immunotherapy CONNECT.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. View post-publication updates from the Society for Immunotherapy of Cancer on SITC CONNECT.

Latest Tweets

Editor-in-Chief

Dr. Pedro Romero is full Professor of Tumor Immunology, at the Department of Fundamental Oncology, Faculty of Biology and Medicine at the University of Lausanne and Ludwig Cancer Research Center, Switzerland. In his early work, Dr. Romero was among the first to use fluorescent pMHC multimers to identify and characterize tumor antigen specific T cells infiltrating tumors in melanoma patients and pioneered modern immunomonitoring approaches to follow anti-tumor T cell responses in cancer patients. His current interests are focused on cancer immunotherapy, the understanding of tumor immune system interactions and T cell recognition of tumor antigens and molecular mechanisms governing specific T cell activation and differentiation. The work of the Romero lab has resulted in more than 290 articles published in peer reviewed journals and several patents.

Advertisement

Annual Journal Metrics

Advertisement